Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors by rpadmin | Mar 21, 2024 | Eisbach
March Biosciences and Cancer Focus Fund Announce $4.8 Million Investment to Support a Phase 2 Clinical Trial of Novel CAR-T Therapy for T-Cell Lymphoma by rpadmin | Nov 9, 2023 | March
Cancer Focus Fund invests $4.8M into Houston-based March Biosciences by rpadmin | Nov 9, 2023 | March
ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS‑001 in Relapsed or Refractory Advanced Solid Tumors by rpadmin | Sep 28, 2023 | ImmunoGenesis
Houston Oncology Summit: MD Anderson’s VP of industry relations talks about partnering (Video) by rpadmin | Sep 21, 2023 | Uncategorized